Five9 Inc vs Stryker Corporation — how do they compare? Five9 Inc trades at $36.4 (market cap $2.63B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 40.4× Five9 Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Five9 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five9 Inc for 72 Days and Stryker Corporation for 21 Days on average.
| FIVN | SYK | |
|---|---|---|
Market Cap | $2.63B | $106.24B |
Volume | 1,864,393 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $38.65 | $388.35 |
52-Week Low | $13.61 | $269.75 |
Typical Hold Time | 72 Days | 21 Days |
Enterprise Value | $2.78B | $117.70B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $36.4, up 7.76% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue growth is accelerating, reaching $1.15B in 2025, while net income turned positive at $39.42M. The stock is near its 52-week high, supported by strong AI-driven subscription growth and leadership in the contact center-as-a-service market.
Outlook remains positive given robust AI revenue growth and raised guidance, but risks include high valuation multiples and insider selling. Analyst consensus is bullish with a $34 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further upside.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →